Dr. PH Rathkjen - Porcine Reproductive & Respiratory Syndrome (PRRS) around the World –...

PH RathkjenSr. Global Technical manager PRRS

Boehringer Ingelheim Animal Health GmbH

– What’s new regarding Global cross-protection against PRRS?

PRRS from around the world

From 22 years experienceof heterologous protection against the economically most important disease across the globe in19 countriesin Asia, Europe and North America

Real world situation· Low Immunity level + High Pathogen challenge

The solution is bigger than the bottle· Maximize immunity & Minimize exposure

What isimportant tocontrolPRRSV?

People are the most important Gilts

replacement proceduresare the most

important

Location is the most

important What about

pig Flow?

You also need

a good Immunity

Do we need to take

PRRSV diversityInto

Consideration?

HeterologousProtection!

No matter the virus.

That is whatYou

Need!

North America: PRRSV type IIsome type I

Most South America:

FreeAustralia:Free

Eastern Europe: PRRSV type I (2,3)

Western Europe:PRRSV type I (1) some type II

Asia:PRRSV type II (HP) some type I

Our basic understanding of PRRSV global distribution

Results: Differences between vaccinated and challenge control animals were statistically significant (P<0.05) in all studies.

Conclusion:

· Under the conditions of these studies, Ingelvac PRRS® MLV significantly reduced lung lesions in multiple challenge models which used genetically diverse heterologous PRRSV isolates.

Homology (%)

94%100%90%89%90%87%87%89%89%87%87%88%86%87%

NorthAmerica

EuropeAsia

Heterologous protection fromA 22 year old PRRS MLV vaccinedocumented globally

ChinaGuo, IPVS 2008

Fang, APVS 2009Liu, IPVS 2010Ao, IPVS 2010Lin, IPVS 2010

Zhu, IPVS 2011Yao, APVS 2011Fang, IPVS 2012Peng, IPVS 2012

Wei, Vaccine 2013

Lager, Vaccine 2014

Xu IPVS 2016Tian IPVS 2016

Huang IPVS 2016

KoreaLee, APVS 2015

Kang, APVS 2015Seo, APVS 2015

Jung, Vet, Micr. 2016Lyoo, Virology 2016

Bae, IPVS 2016Jongyoung, IPVS 2016

Lee, IPVS 2016

VietnamLager, Vaccine 2014

ThailandMeedacha, APVS 2009Kongtes, APVS 2011

Krualoy, IPVS 2012Poommarin, IPVS 2016Duanghwae, IPVS 2016Duanghwae , IPVS 2016

PhilipinesManabat, IPVS 2010

DenmarkNielsen, Vet Micr 1997

Kvisgaard PhD thesis 2013Kristensen, SEGES 2016

GermanyPesch, IPVS 2000

Nickoll, IPVS 2002Medveczkyet, Tier. Um. 2002

Kovacs, 2003Heller, IPVS 2004

Schröder , IPVS 2004Schoun , 2007

HungaryBelgium

USA Osorio, Leman 1998Halbur, Leman 1999

Roof, IPVS 2000Opriessnig, JSHAP 2005

Cano , Vaccine 2007Zuckerman, Vet Micr 2007

Charerntantanakol, Vet Imm & Imm 2006Waddell, AASV 2008Jordan, Leman 2009Reicks, Leman 2010

Miller, AASV 2011Garbes,Leman 2011

Linhares, Vaccine 2011Garbes, AASV 2012

Li, BioMed Res. 2014Dee, AASV 2014

Patterson, Leman 2013 and AASV 2014Patterson, Leman 2016

Haiwick, AASV 2016Haiwick, AASV 2016

Ouyang, Vet Res 2016

MexicoAngulo, Leman 2007

Diaz, AASV 2011Diaz IPVS 2012

Centeno, IPVS 2016

CanadaDesrosiers, APVS 2007

JapanMuehlenthaler, 2012

Kitano, APVS 2015

Worldwide documentation

Japanese isolate bs403929 (internal RD data 2012)

EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL

USA SDSU-73 2016

USA, 1-7-4- 2016

China HP-PRRS 2013

Korean PRRS isolates 2015

· Japanese isolate bs403929

EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL

internal RD data 2012

28 days

VaccinationIngelvac

PRRS® MLV

3 WOA 2 X 20PRRS neg.

· Japanese isolate bs403929

· EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL

· internal RD data 2012

BloodWeight

BloodWeight

BloodWeightBlood Blood

14 days

Blood

Design Parameters Results Moving graphs

Design Parameters Results Moving graphs

Fever (6,7 days vs 3,9 days)

Serum viremia

BAL d 42

Diluent MLV0

0.1

0.2

0.3

0.4

0.5

0.6

0.56 0.54

0.25

0.44

ADWG by group and study period

Vaccination periodChallenge period

ADW

G kg

P=0,0040

Diluent MLV0

5

10

15

20

Percent pneumonia

Average lung lesion

Treatment group

Perc

ent c

onso

lidati

on

P=0,0045

EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012

EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012

Design Parameters Results Moving graphs

EFFICACY OF INGELVAC PRRS MLV FOR PROTECTION AGAINST AN ASIAN PRRSV ISOLATE IN A RESPIRATORY CHALLENGE MODEL. internal BI R+D data 2012

Design Parameters Results Moving graphs

28 days

28 doa 2 X 22PRRS neg.

Blood Blood BloodBlood Blood

21 days

BloodBlood Blood

0 7 14 21 42353228

VaccinationIngelvac

PRRS® MLV

Design Parameters Results Moving graphs

Survival curve

0102030405060708090

100

V/C Non-V/C Strict controls

Surv

ival

rate

in %

Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143

Design Parameters Results Moving graphs

Percent PCR positive & body temperature

chall

enge d3

0d3

1d3

2 d33

d34

d35

d36

d37

d38

d39

d40

d41

d42

d43

d44

d45

d46

d47

d48

Necrop

sy38.5

39

39.5

40

40.5

41

41.5

0

10

20

30

40

50

60

70

80

90

100

V/C group -PCR NV/C group - PCR V/C group - temp NV/C group -temp

Bod

y te

mpe

ratu

re in

°C

% P

CR

pos

itive

s

Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143

Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143

Design Parameters Results Moving graphs

Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143

Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143

Wie et al, Vaccine 2013. Immunization of pigs with a type 2 modified live PRRSV vaccine prevents the development of a deadly long lasting hyperpyrexia in a challenge study with highly pathogenic PRRSVJX143

Design Parameters Results Moving graphs

VaccinationIngelvac

PRRS® MLV 35 days

21 doa4 X 301 x 10PRRS neg. Blood Blood BloodBlood Blood

21 days

BloodBlood Blood

d0 7 14 21 45423835

Blood

49

Daily monitoring clinic, temperature d0 – d49

Strict controls 2 NV --> chall. Diff.

strains (lineage 1 or 5) 2 Vax--> chall. Diff.

strains (lineage 1 or 5)

Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,

Design Parameters Results Moving graphs

Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,

Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,

Jeung et al, Vet Micr. 2015. Evaluation of a 20 year old PRRS modified live vaccine (Ingelvac PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea,

Patterson 2016

Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge, Patterson et al, Leman 2016

Design Parameters Results Moving graphs

28 days

159 PRRSV Neg

28 DOA

BloodWeight

ClinTemp

BloodWeightTempClin

NecropsyWeight Temp

Serum Clin

BloodTemp

BloodTemp

14 days

BloodTemp Blood, Temp

0 7 14 21 42352928 31

IngelvacPRRS® MLV

Group n Treatment

1 45 Ingelvac PRRS® MLV

2 45 Fostera® PRRS

3 65 Placebo

Design Parameters Results Moving graphs

Day 42 Percent Lung Lesions (Median)

asignificantly different from the placebo at P≤0.05

Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

Design Parameters Results Moving graphs

Post-challenge ADWG

Group Treatment ADWG in lbs.

1 Ingelvac PRRS® MLV 0.61a

2 Fostera® PRRS 0.49a*

3 Placebo 0.24b

asignificantly different from the placebo at P≤0.05*different from Ingelvac PRRS® MLV at P≤0.1

Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

Design Parameters Results Moving graphs

Patterson et al, Leman 2016. Efficacy of Ingelvac PRRS MLV against a heterologous PRRSV 1-7-4 RFLP Challenge,

Design Parameters Results Moving graphs

28 days

90 PRRSV Neg

21 DOA

VirusWeight

ClinTemp

VirusWeightTempClin

NecropsyWeight Temp

Serum Clin

VirusTemp

VirusTemp

70 days

VirusTemp Virus

0 7 14 21 38352928 31

IngelvacPRRS® MLV

42 70

Temp daily 14 days, then weekly

SDSU-73

Group VX Cont Chal log

1 10 10 4

2 10 10 3

3 10 10 2

4 10 10 1

5 10 no

Design Parameters Results Moving graphs

G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

This study has relevance in the field as implementation of vaccine in a systematic and coordinated methodology in a “system-based” and “area/region-based” program can mitigate the consequences of PRRSV infection – subsequently improving health and performance – and may reduce the level of challenge virus within and between vaccinated populations over-time further limiting the consequences of infection in vaccinated populationsReid Philips, AASV 2016

Design Parameters Results Moving graphs

G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

G. Haiwick, et al. IPVS 2016. Evaluation of porcine reproductive and respiratory syndrome virus (PRRSV) challenge dose in vaccinated pigs

PRRS immunity across the world

Wei, Vaccine 2013

Jeung, Vet, Micr. 2016Patterson 2016

Muehlenthaler, 2012

Haiwick 2016

What’s new on immunological cross-protection

■ Genotype does not predict the level of protection■ Nothing new!

■ Geography does not predict the level of protection■ Nothing new!

■ Challenge dose plays an important role in the level of efficacy■ Reduction of wild type circulation is important

Reid Philips Enrique Mondaca Xavier de Paz Carlo Maala

Ryan Huang Oliver Duran Joe Victoria A. PattersonG. Haiwick

Thanks to